Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR - Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma

被引：0
|
作者：
Venugopalan, Abhilash [1 ]
Khoa Nguyen [1 ]
Lynberg, Matthew [1 ]
Maity, Tapan [1 ]
Qi, Yue [1 ]
Roper, Nitin [1 ]
Cultraro, Constance [1 ]
Chan, King [1 ]
Misra, Vikram [1 ]
Thorkell, Andresson [1 ]
Zhang, Xu [1 ]
Crooks, Daniel [1 ]
Linehan, W. [1 ]
Lane, Andrew [2 ]
Guha, Udayan [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] Univ Kentucky, Lexington, KY 40506 USA
来源：
FASEB JOURNAL | 2020年 / 34卷
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1096/fasebj.2020.34.s1.00602
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
    Hu, Yijuan
    Xiao, Lili
    Yang, Nong
    Zhang, Yongchang
    THORACIC CANCER, 2019, 10 (05) : 1252 - 1255
  • [2] The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
    Wu, Shang-Gin
    Liu, Yi-Nan
    Tsai, Meng-Feng
    Chang, Yih-Leong
    Yu, Chong-Jen
    Yang, Pan-Chyr
    Yang, James Chih-Hsin
    Wen, Yueh-Feng
    Shih, Jin-Yuan
    ONCOTARGET, 2016, 7 (11) : 12404 - 12413
  • [3] Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
    Mur, Emilie Bousquet
    Bernardo, Sara
    Papon, Laura
    Mancini, Maicol
    Fabbrizio, Eric
    Goussard, Marion
    Ferrer, Irene
    Giry, Anais
    Quantin, Xavier
    Pujol, Jean-Louis
    Calvayrac, Olivier
    Moll, Herwig P.
    Glasson, Yael
    Pirot, Nelly
    Turtoi, Andrei
    Canamero, Marta
    Wong, Kwok-Kin
    Yarden, Yosef
    Casanova, Emilio
    Soria, Jean-Charles
    Colinge, Jacques
    Siebel, Christian W.
    Mazieres, Julien
    Favre, Gilles
    Paz-Ares, Luis
    Maraver, Antonio
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (02): : 612 - 624
  • [4] Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor
    Chen, H.
    Wang, W.
    Li, X.
    Xu, C.
    Zhu, Y.
    Du, K.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
  • [5] The KIF5B-RET Fusion as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
    Zhu, Y.
    Wang, W.
    Xu, C.
    Zhang, Q.
    Zhuang, W.
    Du, K.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
  • [6] EGFR - TYROSINE KINASE INHIBITOR AS FIRST LINE TREATMENT IN METASTATIC LUNG ADENOCARCINOMA
    Febriani, Anna
    Wulandari, Laksmi
    Hariadi, Slamet
    Wibisono, Yusuf
    RESPIROLOGY, 2010, 15 : 67 - 67
  • [7] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
  • [8] Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases
    Uruga, Hironori
    Fujii, Takeshi
    Nakamura, Nobuyuki
    Moriguchi, Shuhei
    Kishi, Kazuma
    Takaya, Hisashi
    RESPIROLOGY CASE REPORTS, 2020, 8 (02):
  • [9] Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
    Luo, Jia
    Makhnin, Alex
    Tobi, Yosef
    Ahn, Linda
    Hayes, Sara A.
    Iqbal, Afsheen
    Ng, Kenneth
    Arcila, Maria E.
    Riely, Gregory J.
    Kris, Mark G.
    Yu, Helena A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 55 - 64
  • [10] The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
    Zhu, You-cai
    Wang, Wen-xian
    Zhang, Qu-xia
    Xu, Chun-wei
    Zhuang, Wu
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    CLINICAL LUNG CANCER, 2019, 20 (01) : E73 - E76
12345